Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study
This article is for subscribers only.
Eli Lilly & Co. said it will pull its Xigris sepsis drug from all markets after the treatment failed to reduce deaths in a study.
The withdrawal may cost Lilly $75 million to $95 million in the fourth quarter of 2011, or about 5 cents a share, the Indianapolis-based company said in a statement. Lilly’s 2011 adjusted earnings forecast remained at $4.30 to $4.35 a share.